Ads
related to: docetaxel chemotherapy
Search results
Lung cancer pill outperforms chemotherapy in clinical trials
The Hill via Yahoo News· 2 years agoStory at a glance Lung cancer treatments include immunotherapy, chemotherapy and drugs given orally....
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
Benzinga via Yahoo Finance· 2 years agoAmgen Inc (NASDAQ: AMGN) announced detailed results from the global Phase 3 CodeBreaK 200 trial....
Merck suffers bad week as 3 Keytruda combination trials fail
BioPharma Dive via Yahoo Finance· 5 months agoThe setbacks for Merck demonstrate the challenge drug developers face in improving on Keytruda,...
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Benzinga via Yahoo Finance· 2 years agoMerck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy...
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
Zacks via Yahoo Finance· 2 years agoGSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with...
Bristol Myers says KRAS drug succeeds in key trial
BioPharma Dive via Yahoo Finance· 2 months agoConfirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set...
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
Benzinga via Yahoo Finance· 1 year agoAileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b...
Gilead ADC medicine misses goal in closely watched lung cancer study
BioPharma Dive via Yahoo Finance· 4 months agoTrodelvy didn’t outperform chemotherapy in a large study of people with a common lung tumor, a...
Breast cancer patients devote hours for treatments
KLAS articles via Yahoo News· 5 months agoLAS VEGAS (KLAS) — For people with breast cancer, the time spent receiving treatment, coordinating care and traveling to doctor’s appointments can be...
Why Is HIV Drug Giant Gilead Stock Falling Monday?
Benzinga via Yahoo Finance· 4 months agoGilead Sciences Inc (NASDAQ:GILD) said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated...
